Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Dallah Healthcare Co's interest expense for the
three
months ended in Mar. 2026 was ﷼ -43 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was ﷼-165 Mil.
Dallah Healthcare Co (SAU:4004) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Warning Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Dallah Healthcare Co interest coverage is 3.32, which is low.
Dallah Healthcare Co Interest Expense Historical Data
* Premium members only.
The historical data trend for Dallah Healthcare Co's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ﷼-165 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dallah Healthcare Co (SAU:4004) has a Interest Expense of ﷼-165 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Dallah Healthcare Co and its competitors.
Is Dallah Healthcare Co's Interest Expense too high?
Dallah Healthcare Co's current Interest Expense is ﷼-165 Mil. Overall, Dallah Healthcare Co has a GF Score™ of 93/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dallah Healthcare Co's Interest Expense compare to HCA and THC?
Dallah Healthcare Co's Interest Expense of ﷼-165 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Healthcare Providers & Services company?
A good Interest Expense depends on the Healthcare Providers & Services industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Dallah Healthcare Co and its competitors. Dallah Healthcare Co's current Interest Expense is ﷼-165 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dallah Healthcare Co stock overvalued right now?
Based on GuruFocus' analysis, Dallah Healthcare Co (SAU:4004) is currently considered Possible Value Trap. The stock's GF Value™ is ﷼206.59, compared to a current price of ﷼106.40 — trading 48.5% below its estimated fair value. The current Interest Expense is ﷼-165 Mil. Dallah Healthcare Co's overall GF Score™ is 93/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Dallah Healthcare Co (SAU:4004), the current Interest Expense is ﷼-165 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dallah Healthcare Co (SAU:4004) Overvalued in 2026?
Based on GuruFocus' analysis, Dallah Healthcare Co stock appears to be undervalued.
The current stock price of ﷼106.40 is trading 48.5% below its estimated GF Value™ of ﷼206.59.
GuruFocus considers Dallah Healthcare Co to be Possible Value Trap.
Key valuation signals for SAU:4004:
Interest Expense: ﷼-165 Mil
GF Value™: ﷼206.59 vs. price of ﷼106.40 (48.5% below fair value)
No single metric tells the full story. See the SAU:4004 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dallah Healthcare Co provides and operates healthcare programs and utilities in the Kingdom of Saudi Arabia. The objectives of the company include operating, managing, and maintaining the healthcare entities, wholesale medicines, and retail of medical and surgical equipment, prosthetics, and devices for the disabled, hospital equipment, and manufacturing medicines, pharmaceuticals, herbals, health, cosmetics, detergents, disinfectants, and packaging in the Kingdom of Saudi Arabia. The reportable segments of the company are Medical Facilities and Pharmacies, and Distribution of Pharmaceutical Products. The company generates the majority of its revenue from the Medical Facilities and Pharmacies segment.
93GF Score
Get the complete analysis for SAU:4004
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4004 has been successfully added to your 
